Mirum Pharmaceuticals
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Mirum Pharmaceuticals sits in the top decile of US sponsors by registered trial count (#568 of 15,742 sponsors by registered trial count).
Mirum Pharmaceuticals: 28 sponsored US clinical trials, 5 recruiting.
Mirum Pharmaceuticals sponsors 28 registered US clinical trials on ClinicalTrials.gov, 5 of them currently recruiting, and 18 completed. 8 of these trials are in Phase 3-4 (later-stage) and 17 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Progressive Familial Intrahepatic Cholestasis (PFIC), with 2 trials.
Top-decile sponsor footprint
Mirum Pharmaceuticals ranks in the top decile of sponsors by registered trial count (#568 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
18 of 20 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (90.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
28 total, page 1 of 1
A Trial Evaluating Brelovitug vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection (AZURE-4)
NCT07298330
Study of MRM-3379 in Male Participants With Fragile X Syndrome (BLOOM)
NCT07209462
Evaluation of Maralixibat in Pruritus Associated With General Cholestatic Liver Disease (EXPAND)
NCT06553768
Long-Term SafEty and Clinical Outcomes of LivmArli in Patients in the United States (LEAP-US)
NCT06193928
A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis
NCT05050136
A Trial Evaluating BJT-778 vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection
NCT06907290
A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)
NCT04663308
The REPLACE Registry for Cholbam® (Cholic Acid)
NCT03115086
A Study to Evaluate the Safety and Tolerability of Maralixibat in Infant Participants With Cholestatic Liver Diseases Including Progressive Familial Intrahepatic Cholestasis (PFIC) and Alagille Syndrome (ALGS).
NCT04729751
Evaluation of Maralixibat in Biliary Atresia Response Post-Kasai
NCT04524390
A Placebo-controlled Study of Volixibat in Subjects With Elevated Serum Bile Acids Associated With Intrahepatic Cholestasis of Pregnancy (OHANA)
NCT04718961
Study to Evaluate Patients With Cerebrotendinous Xanthomatosis (RESTORE)
NCT04270682
MRX-800: A Long-Term Safety Study of Maralixibat in the Treatment of Cholestatic Liver Disease in Subjects Who Previously Participated in a Maralixibat Study
NCT04168385
An Extension Study of Maralixibat in Patients With Progressive Familial Intrahepatic Cholestasis (PFIC)
NCT04185363
A Study to Evaluate the Efficacy and Safety of Maralixibat in Subjects With Progressive Familial Intrahepatic Cholestasis (MARCH-PFIC)
NCT03905330
Volixibat (SHP626) in the Treatment of Adults With Nonalcoholic Steatohepatitis (NASH)
NCT02787304
A Study to Investigate How the Study Drug SHP626 is Eliminated From the Body After One Dose
NCT02571192
Study to Assess the Relative Potency of Multiple Oral Doses of LUM001 and SHP626 in Overweight and Obese Adults as Assessed by Fecal Bile Acid Excretion
NCT02475317
An Extension Study to Evaluate the Long-Term Safety and Durability of Effect of LUM001 in the Treatment of Cholestatic Liver Disease in Pediatric Subjects With Alagille Syndrome
NCT02117713
Safety and Tolerability Study of SHP626 in Overweight and Obese Adults
NCT02287779
Evaluation of LUM001 in the Reduction of Pruritus in Alagille Syndrome
NCT02057692
Validation of the Itch Reported Outcome (ItchRO) Diaries in Pediatric Cholestatic Liver Disease
NCT02131623
Open Label Study to Evaluate Efficacy and Long Term Safety of LUM001 (Maralixibat) in the Treatment of Cholestatic Liver Disease in Patients With Progressive Familial Intrahepatic Cholestasis
NCT02057718
Open Label Study to Evaluate Safety and Efficacy of LUM001 in Patients With Primary Sclerosing Cholangitis
NCT02061540
Phase 2 Study to Evaluate LUM001 in Combination With Ursodeoxycholic Acid in Patients With Primary Biliary Cirrhosis
NCT01904058
Efficacy of To Be Marketed (TBM) Cholic Acid Capsules Used to Treat Children With Inborn Errors of Bile Acid Synthesis
NCT01115582
Open Label, Continuation Study of Cholic Acid in Subjects With Inborn Errors of Bile Acid Synthesis
NCT01438411
Compassionate Treatment of Patients With Inborn Errors of Bile Acid Metabolism With Cholic Acid
NCT00007020
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 14 |
| Phase 3 | 8 |
What is open in the Mirum Pharmaceuticals pipeline
5 recruiting of 28 indexed (18% open); 18 completed (64%).
Phase mix: 8 late (III/IV) vs 17 early (I/II) (early-phase heavy).
Top condition: Progressive Familial Intrahepatic Cholestasis (PFIC) (2 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Mirum Pharmaceuticals: open-pipeline peers nationwide
Peers matched on 28 registered trials and 18% open enrollment, not the therapeutic-area sidebar.
Mirum Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 28 trials (± recruiting share)
- Axsome Therapeutics · 28 trials · 21% recruiting
- Benaroya Research Institute · 28 trials · 14% recruiting
- CAMC Health System · 28 trials · 11% recruiting
- CTI BioPharma · 28 trials · 0% recruiting
Sponsors near 18% open enrollment (± trial volume)
- Kite, A Gilead Company · 18% recruiting · 28 trials
- Columbia University · 18% recruiting · 958 trials
- West Virginia University · 18% recruiting · 122 trials
- Hospital for Special Surgery, New York · 18% recruiting · 194 trials
Related
What to do with this Mirum Pharmaceuticals page
28 registered trials is a research-attention snapshot, not an endorsement of Mirum Pharmaceuticals or any single study.
- 5 of Mirum Pharmaceuticals's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Progressive Familial Intrahepatic Cholestasis (PFIC) is the condition Mirum Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Progressive Familial Intrahepatic Cholestasis (PFIC) trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Mirum Pharmaceuticals pipeline card: 28 registered trials from official public datasets.Report a data error.